Global and United States Tourette Syndrome Drug In-Depth Research Report 2017-2022
The report is based on the market historical data from 2012 to 2016 and forecast the market trend from 2017 to 2022.
This report focuses on the U.S. market and presents volume and value of market share by players, by regions, by product type, by consumers and also changes in prices. As an in-depth report, it covers all details inside analysis and opinions in Tourette Syndrome Drug industry.
Major Companies
Abide Therapeutics Inc
Catalyst Pharmaceuticals Inc
Neurocrine Biosciences Inc
Psyadon Pharmaceuticals Inc
Reviva Pharmaceuticals Inc
Synchroneuron Inc
Teva Pharmaceutical Industries Ltd
Therapix Biosciences Ltd
Key Regions
North America
United States
California
Texas
New York
Others
Canada
Latin America
Mexico
Brazil
Argentina
Others
Europe
Germany
United Kingdom
France
Italy
Spain
Russia
Netherland
Others
Asia & Pacific
China
Japan
India
Korea
Australia
Southeast Asia
Indonesia
Thailand
Philippines
Vietnam
Singapore
Malaysia
Others
Africa & Middle East
South Africa
Egypt
Turkey
Saudi Arabia
Iran
Others
Main types of products
Tourette Syndrome Drug Market, byD-5213
Tourette Syndrome Drug Market, byP-115
Tourette Syndrome Drug Market, bytetrabenazine ER
Tourette Syndrome Drug Market, byopipam Hydrochloride
Tourette Syndrome Drug Market, byhers
Tourette Syndrome Drug Market, by Key Consumers
Research Center
Hospital
Clinic
Others
This report focuses on the U.S. market and presents volume and value of market share by players, by regions, by product type, by consumers and also changes in prices. As an in-depth report, it covers all details inside analysis and opinions in Tourette Syndrome Drug industry.
Major Companies
Abide Therapeutics Inc
Catalyst Pharmaceuticals Inc
Neurocrine Biosciences Inc
Psyadon Pharmaceuticals Inc
Reviva Pharmaceuticals Inc
Synchroneuron Inc
Teva Pharmaceutical Industries Ltd
Therapix Biosciences Ltd
Key Regions
North America
United States
California
Texas
New York
Others
Canada
Latin America
Mexico
Brazil
Argentina
Others
Europe
Germany
United Kingdom
France
Italy
Spain
Russia
Netherland
Others
Asia & Pacific
China
Japan
India
Korea
Australia
Southeast Asia
Indonesia
Thailand
Philippines
Vietnam
Singapore
Malaysia
Others
Africa & Middle East
South Africa
Egypt
Turkey
Saudi Arabia
Iran
Others
Main types of products
Tourette Syndrome Drug Market, byD-5213
Tourette Syndrome Drug Market, byP-115
Tourette Syndrome Drug Market, bytetrabenazine ER
Tourette Syndrome Drug Market, byopipam Hydrochloride
Tourette Syndrome Drug Market, byhers
Tourette Syndrome Drug Market, by Key Consumers
Research Center
Hospital
Clinic
Others
CHAPTER ONE GLOBAL TOURETTE SYNDROME DRUG MARKET OVERVIEW
1.1 Global Tourette Syndrome Drug Market Sales Volume Revenue and Price 2012-2017
1.2 Tourette Syndrome Drug, by -5213 2012-2017
1.2.1 Global Tourette Syndrome Drug Sales Market Share by -5213 2012-2017
1.2.2 Global Tourette Syndrome Drug Revenue Market Share by -5213 2012-2017
1.2.3 Global Tourette Syndrome Drug Price by -5213 2012-2017
1.2.4
1.2.5
1.3 Tourette Syndrome Drug, by -115 2012-2017
1.3.1 Global Tourette Syndrome Drug Sales Market Share by -115 2012-2017
1.3.2 Global Tourette Syndrome Drug Revenue Market Share by -115 2012-2017
1.3.3 Global Tourette Syndrome Drug Price by -115 2012-2017
1.3.4
1.3.5
1.4 Tourette Syndrome Drug, by etrabenazine ER 2012-2017
1.4.1 Global Tourette Syndrome Drug Sales Market Share by etrabenazine ER 2012-2017
1.4.2 Global Tourette Syndrome Drug Revenue Market Share by etrabenazine ER 2012-2017
1.4.3 Global Tourette Syndrome Drug Price by etrabenazine ER 2012-2017
1.4.4
1.4.5
1.5 Tourette Syndrome Drug, by pipam Hydrochloride 2012-2017
1.5.1 Global Tourette Syndrome Drug Sales Market Share by pipam Hydrochloride 2012-2017
1.5.2 Global Tourette Syndrome Drug Revenue Market Share by pipam Hydrochloride 2012-2017
1.5.3 Global Tourette Syndrome Drug Price by pipam Hydrochloride 2012-2017
1.5.4
1.5.5
1.6 Tourette Syndrome Drug, by ers 2012-2017
1.6.1 Global Tourette Syndrome Drug Sales Market Share by ers 2012-2017
1.6.2 Global Tourette Syndrome Drug Revenue Market Share by ers 2012-2017
1.6.3 Global Tourette Syndrome Drug Price by ers 2012-2017
1.6.4
1.6.5
CHAPTER TWO UNITED STATES TOURETTE SYNDROME DRUG MARKET OVERVIEW
2.1 United States Tourette Syndrome Drug Market Sales Volume Revenue and Price 2012-2017
2.2 Tourette Syndrome Drug, by -5213 2012-2017
2.2.1 United States Tourette Syndrome Drug Sales Market Share by -5213 2012-2017
2.2.2 United States Tourette Syndrome Drug Revenue Market Share by -5213 2012-2017
2.2.3 United States Tourette Syndrome Drug Price by -5213 2012-2017
2.2.4
2.2.5
2.3 Tourette Syndrome Drug, by -115 2012-2017
2.3.1 United States Tourette Syndrome Drug Sales Market Share by -115 2012-2017
2.3.2 United States Tourette Syndrome Drug Revenue Market Share by -115 2012-2017
2.3.3 United States Tourette Syndrome Drug Price by -115 2012-2017
2.3.4
2.3.5
2.4 Tourette Syndrome Drug, by etrabenazine ER 2012-2017
2.4.1 United States Tourette Syndrome Drug Sales Market Share by etrabenazine ER 2012-2017
2.4.2 United States Tourette Syndrome Drug Revenue Market Share by etrabenazine ER 2012-2017
2.4.3 United States Tourette Syndrome Drug Price by etrabenazine ER 2012-2017
2.4.4
2.4.5
2.5 Tourette Syndrome Drug, by pipam Hydrochloride 2012-2017
2.5.1 United States Tourette Syndrome Drug Sales Market Share by pipam Hydrochloride 2012-2017
2.5.2 United States Tourette Syndrome Drug Revenue Market Share by pipam Hydrochloride 2012-2017
2.5.3 United States Tourette Syndrome Drug Price by pipam Hydrochloride 2012-2017
2.5.4
2.5.5
2.6 Tourette Syndrome Drug, by ers 2012-2017
2.6.1 United States Tourette Syndrome Drug Sales Market Share by ers 2012-2017
2.6.2 United States Tourette Syndrome Drug Revenue Market Share by ers 2012-2017
2.6.3 United States Tourette Syndrome Drug Price by ers 2012-2017
2.6.4
2.6.5
CHAPTER THREE TOURETTE SYNDROME DRUG BY REGIONS 2012-2017
3.1 Global Tourette Syndrome Drug Sales Market Share by Regions 2012-2017
3.2 Global Tourette Syndrome Drug Revenue Market Share by Regions 2012-2017
3.3 Global Tourette Syndrome Drug Price by Regions 2012-2017
3.4 North America
3.4.1 United States
3.4.1.1 California
3.4.1.2 Texas
3.4.1.3 New York
3.4.1.4 Others in United States
3.4.2 Canada
3.5 Latin America
3.5.1 Mexico
3.5.2 Brazil
3.5.3 Argentina
3.5.4 Others in Latin America
3.6 Europe
3.6.1 Germany
3.6.2 United Kingdom
3.6.3 France
3.6.4 Italy
3.6.5 Spain
3.6.6 Russia
3.6.7 Netherland
3.6.8 Others in Europe
3.7 Asia & Pacific
3.7.1 China
3.7.2 Japan
3.7.3 India
3.7.4 Korea
3.7.5 Australia
3.7.6 Southeast Asia
3.7.6.1 Indonesia
3.7.6.2 Thailand
3.7.6.3 Philippines
3.7.6.4 Vietnam
3.7.6.5 Singapore
3.7.6.6 Malaysia
3.7.6.7 Others in Southeast Asia
3.8 Africa & Middle East
3.8.1 South Africa
3.8.2 Egypt
3.8.3 Turkey
3.8.4 Saudi Arabia
3.8.5 Iran
3.8.6 Others in Africa & Middle East
CHAPTER FOUR GLOBAL TOURETTE SYNDROME DRUG BY COMPANIES 2012-2017
4.1 Global Tourette Syndrome Drug Sales Volume Market Share by Companies 2012-2017
4.2 Global Tourette Syndrome Drug Revenue Share by Companies 2012-2017
4.3 Global Top Companies Tourette Syndrome Drug Key Product Model and Market Performance
4.4 Global Top Companies Tourette Syndrome Drug Key Target Consumers and Market Performance
CHAPTER FIVE UNITED STATES TOURETTE SYNDROME DRUG BY COMPANIES 2012-2017
5.1 United States Tourette Syndrome Drug Sales Volume Market Share by Companies 2012-2017
5.2 United States Tourette Syndrome Drug Revenue Share by Companies 2012-2017
5.3 United States Top Companies Tourette Syndrome Drug Key Product Model and Market Performance
5.4 United States Top Companies Tourette Syndrome Drug Key Target Consumers and Market Performance
CHAPTER SIX GLOBAL TOURETTE SYNDROME DRUG BY CONSUMER 2012-2017
6.1 Global Tourette Syndrome Drug Sales Market Share by Consumer 2012-2017
6.2 Research Center
6.3 Hospital
6.4 Clinic
6.5 Others
6.6 Consuming Habit and Preference
CHAPTER SEVEN GLOBAL TOURETTE SYNDROME DRUG BY CONSUMER 2012-2017
7.1 Global Tourette Syndrome Drug Sales Market Share by Consumer 2012-2017
7.2 Research Center
7.3 Hospital
7.4 Clinic
7.5 Others
7.6 Consuming Habit and Preference
CHAPTER EIGHT TOP COMPANIES PROFILE
8.1 Abide Therapeutics Inc
8.1.1 Abide Therapeutics Inc Company Details and Competitors
8.1.2 Abide Therapeutics Inc Key Tourette Syndrome Drug Models and Performance
8.1.3 Abide Therapeutics Inc Tourette Syndrome Drug Business SWOT Analysis and Forecast
8.1.4 Abide Therapeutics Inc Tourette Syndrome Drug Sales Volume Revenue Price Cost and Gross Margin
8.2 Catalyst Pharmaceuticals Inc
8.2.1 Catalyst Pharmaceuticals Inc Company Details and Competitors
8.2.2 Catalyst Pharmaceuticals Inc Key Tourette Syndrome Drug Models and Performance
8.2.3 Catalyst Pharmaceuticals Inc Tourette Syndrome Drug Business SWOT Analysis and Forecast
8.2.4 Catalyst Pharmaceuticals Inc Tourette Syndrome Drug Sales Volume Revenue Price Cost and Gross Margin
8.3 Neurocrine Biosciences Inc
8.3.1 Neurocrine Biosciences Inc Company Details and Competitors
8.3.2 Neurocrine Biosciences Inc Key Tourette Syndrome Drug Models and Performance
8.3.3 Neurocrine Biosciences Inc Tourette Syndrome Drug Business SWOT Analysis and Forecast
8.3.4 Neurocrine Biosciences Inc Tourette Syndrome Drug Sales Volume Revenue Price Cost and Gross Margin
8.4 Psyadon Pharmaceuticals Inc
8.4.1 Psyadon Pharmaceuticals Inc Company Details and Competitors
8.4.2 Psyadon Pharmaceuticals Inc Key Tourette Syndrome Drug Models and Performance
8.4.3 Psyadon Pharmaceuticals Inc Tourette Syndrome Drug Business SWOT Analysis and Forecast
8.4.4 Psyadon Pharmaceuticals Inc Tourette Syndrome Drug Sales Volume Revenue Price Cost and Gross Margin
8.5 Reviva Pharmaceuticals Inc
8.5.1 Reviva Pharmaceuticals Inc Company Details and Competitors
8.5.2 Reviva Pharmaceuticals Inc Key Tourette Syndrome Drug Models and Performance
8.5.3 Reviva Pharmaceuticals Inc Tourette Syndrome Drug Business SWOT Analysis and Forecast
8.5.4 Reviva Pharmaceuticals Inc Tourette Syndrome Drug Sales Volume Revenue Price Cost and Gross Margin
8.6 Synchroneuron Inc
8.6.1 Synchroneuron Inc Company Details and Competitors
8.6.2 Synchroneuron Inc Key Tourette Syndrome Drug Models and Performance
8.6.3 Synchroneuron Inc Tourette Syndrome Drug Business SWOT Analysis and Forecast
8.6.4 Synchroneuron Inc Tourette Syndrome Drug Sales Volume Revenue Price Cost and Gross Margin
8.7 Teva Pharmaceutical Industries Ltd
8.7.1 Teva Pharmaceutical Industries Ltd Company Details and Competitors
8.7.2 Teva Pharmaceutical Industries Ltd Key Tourette Syndrome Drug Models and Performance
8.7.3 Teva Pharmaceutical Industries Ltd Tourette Syndrome Drug Business SWOT Analysis and Forecast
8.7.4 Teva Pharmaceutical Industries Ltd Tourette Syndrome Drug Sales Volume Revenue Price Cost and Gross Margin
8.8 Therapix Biosciences Ltd
8.8.1 Therapix Biosciences Ltd Company Details and Competitors
8.8.2 Therapix Biosciences Ltd Key Tourette Syndrome Drug Models and Performance
8.8.3 Therapix Biosciences Ltd Tourette Syndrome Drug Business SWOT Analysis and Forecast
8.8.4 Therapix Biosciences Ltd Tourette Syndrome Drug Sales Volume Revenue Price Cost and Gross Margin
CHAPTER NINE INDUSTRY CHAIN AND SUPPLY CHAIN
9.1 Tourette Syndrome Drug Industry Chain Structure
9.1.1 R&D
9.1.2 Raw Materials (Components)
9.1.3 Manufacturing Plants
9.1.4 Regional Trading (Import Export and Local Sales)
9.1.5 Online Sales Channel
9.1.6 Offline Channel
9.1.7 End Users
9.2 Tourette Syndrome Drug Manufacturing
9.2.1 Key Components
9.2.2 Assembly Manufacturing
9.3 Consumer Preference
9.4 Behavioral Habits
9.5 Marketing Environment
CHAPTER TEN GLOBAL TOURETTE SYNDROME DRUG MARKET SIZE (SALES AND REVENUE) FORECAST (2017-2022)
10.1 Global Tourette Syndrome Drug Sales (K Pcs), Revenue (Million USD) Forecast (2017-2022)
10.2 Global Tourette Syndrome Drug Sales (K Pcs) Forecast by Regions (2017-2022)
10.3 Global Tourette Syndrome Drug Sales (K Pcs) Forecast by Application (2017-2022)
10.4 Global Tourette Syndrome Drug Sales (K Pcs) Forecast by -5213 (2017-2022)
10.5 Global Tourette Syndrome Drug Sales (K Pcs) Forecast by -115 (2017-2022)
10.6 Global Tourette Syndrome Drug Sales (K Pcs) Forecast by etrabenazine ER (2017-2022)
10.7 Global Tourette Syndrome Drug Sales (K Pcs) Forecast by pipam Hydrochloride (2017-2022)
10.8 Global Tourette Syndrome Drug Sales (K Pcs) Forecast by ers (2017-2022)
CHAPTER ELEVEN UNITED STATES TOURETTE SYNDROME DRUG MARKET SIZE (SALES AND REVENUE) FORECAST (2017-2022)
11.1 United States Tourette Syndrome Drug Sales (K Pcs), Revenue (Million USD) Forecast (2017-2022)
11.2 United States Tourette Syndrome Drug Sales (K Pcs) Forecast by Regions (2017-2022)
11.3 United States Tourette Syndrome Drug Sales (K Pcs) Forecast by Application (2017-2022)
11.4 United States Tourette Syndrome Drug Sales (K Pcs) Forecast by -5213 (2017-2022)
11.5 United States Tourette Syndrome Drug Sales (K Pcs) Forecast by -115 (2017-2022)
11.6 United States Tourette Syndrome Drug Sales (K Pcs) Forecast by etrabenazine ER (2017-2022)
11.7 United States Tourette Syndrome Drug Sales (K Pcs) Forecast by pipam Hydrochloride (2017-2022)
11.8 United States Tourette Syndrome Drug Sales (K Pcs) Forecast by ers (2017-2022)
CHAPTER TWELVE DEVELOPMENT TREND AND RESEARCH CONCLUSION
12.1 Development Trend
12.2 Research Conclusion
CHAPTER THIRTEEN METHODOLOGY AND DATA SOURCE
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
1.1 Global Tourette Syndrome Drug Market Sales Volume Revenue and Price 2012-2017
1.2 Tourette Syndrome Drug, by -5213 2012-2017
1.2.1 Global Tourette Syndrome Drug Sales Market Share by -5213 2012-2017
1.2.2 Global Tourette Syndrome Drug Revenue Market Share by -5213 2012-2017
1.2.3 Global Tourette Syndrome Drug Price by -5213 2012-2017
1.2.4
1.2.5
1.3 Tourette Syndrome Drug, by -115 2012-2017
1.3.1 Global Tourette Syndrome Drug Sales Market Share by -115 2012-2017
1.3.2 Global Tourette Syndrome Drug Revenue Market Share by -115 2012-2017
1.3.3 Global Tourette Syndrome Drug Price by -115 2012-2017
1.3.4
1.3.5
1.4 Tourette Syndrome Drug, by etrabenazine ER 2012-2017
1.4.1 Global Tourette Syndrome Drug Sales Market Share by etrabenazine ER 2012-2017
1.4.2 Global Tourette Syndrome Drug Revenue Market Share by etrabenazine ER 2012-2017
1.4.3 Global Tourette Syndrome Drug Price by etrabenazine ER 2012-2017
1.4.4
1.4.5
1.5 Tourette Syndrome Drug, by pipam Hydrochloride 2012-2017
1.5.1 Global Tourette Syndrome Drug Sales Market Share by pipam Hydrochloride 2012-2017
1.5.2 Global Tourette Syndrome Drug Revenue Market Share by pipam Hydrochloride 2012-2017
1.5.3 Global Tourette Syndrome Drug Price by pipam Hydrochloride 2012-2017
1.5.4
1.5.5
1.6 Tourette Syndrome Drug, by ers 2012-2017
1.6.1 Global Tourette Syndrome Drug Sales Market Share by ers 2012-2017
1.6.2 Global Tourette Syndrome Drug Revenue Market Share by ers 2012-2017
1.6.3 Global Tourette Syndrome Drug Price by ers 2012-2017
1.6.4
1.6.5
CHAPTER TWO UNITED STATES TOURETTE SYNDROME DRUG MARKET OVERVIEW
2.1 United States Tourette Syndrome Drug Market Sales Volume Revenue and Price 2012-2017
2.2 Tourette Syndrome Drug, by -5213 2012-2017
2.2.1 United States Tourette Syndrome Drug Sales Market Share by -5213 2012-2017
2.2.2 United States Tourette Syndrome Drug Revenue Market Share by -5213 2012-2017
2.2.3 United States Tourette Syndrome Drug Price by -5213 2012-2017
2.2.4
2.2.5
2.3 Tourette Syndrome Drug, by -115 2012-2017
2.3.1 United States Tourette Syndrome Drug Sales Market Share by -115 2012-2017
2.3.2 United States Tourette Syndrome Drug Revenue Market Share by -115 2012-2017
2.3.3 United States Tourette Syndrome Drug Price by -115 2012-2017
2.3.4
2.3.5
2.4 Tourette Syndrome Drug, by etrabenazine ER 2012-2017
2.4.1 United States Tourette Syndrome Drug Sales Market Share by etrabenazine ER 2012-2017
2.4.2 United States Tourette Syndrome Drug Revenue Market Share by etrabenazine ER 2012-2017
2.4.3 United States Tourette Syndrome Drug Price by etrabenazine ER 2012-2017
2.4.4
2.4.5
2.5 Tourette Syndrome Drug, by pipam Hydrochloride 2012-2017
2.5.1 United States Tourette Syndrome Drug Sales Market Share by pipam Hydrochloride 2012-2017
2.5.2 United States Tourette Syndrome Drug Revenue Market Share by pipam Hydrochloride 2012-2017
2.5.3 United States Tourette Syndrome Drug Price by pipam Hydrochloride 2012-2017
2.5.4
2.5.5
2.6 Tourette Syndrome Drug, by ers 2012-2017
2.6.1 United States Tourette Syndrome Drug Sales Market Share by ers 2012-2017
2.6.2 United States Tourette Syndrome Drug Revenue Market Share by ers 2012-2017
2.6.3 United States Tourette Syndrome Drug Price by ers 2012-2017
2.6.4
2.6.5
CHAPTER THREE TOURETTE SYNDROME DRUG BY REGIONS 2012-2017
3.1 Global Tourette Syndrome Drug Sales Market Share by Regions 2012-2017
3.2 Global Tourette Syndrome Drug Revenue Market Share by Regions 2012-2017
3.3 Global Tourette Syndrome Drug Price by Regions 2012-2017
3.4 North America
3.4.1 United States
3.4.1.1 California
3.4.1.2 Texas
3.4.1.3 New York
3.4.1.4 Others in United States
3.4.2 Canada
3.5 Latin America
3.5.1 Mexico
3.5.2 Brazil
3.5.3 Argentina
3.5.4 Others in Latin America
3.6 Europe
3.6.1 Germany
3.6.2 United Kingdom
3.6.3 France
3.6.4 Italy
3.6.5 Spain
3.6.6 Russia
3.6.7 Netherland
3.6.8 Others in Europe
3.7 Asia & Pacific
3.7.1 China
3.7.2 Japan
3.7.3 India
3.7.4 Korea
3.7.5 Australia
3.7.6 Southeast Asia
3.7.6.1 Indonesia
3.7.6.2 Thailand
3.7.6.3 Philippines
3.7.6.4 Vietnam
3.7.6.5 Singapore
3.7.6.6 Malaysia
3.7.6.7 Others in Southeast Asia
3.8 Africa & Middle East
3.8.1 South Africa
3.8.2 Egypt
3.8.3 Turkey
3.8.4 Saudi Arabia
3.8.5 Iran
3.8.6 Others in Africa & Middle East
CHAPTER FOUR GLOBAL TOURETTE SYNDROME DRUG BY COMPANIES 2012-2017
4.1 Global Tourette Syndrome Drug Sales Volume Market Share by Companies 2012-2017
4.2 Global Tourette Syndrome Drug Revenue Share by Companies 2012-2017
4.3 Global Top Companies Tourette Syndrome Drug Key Product Model and Market Performance
4.4 Global Top Companies Tourette Syndrome Drug Key Target Consumers and Market Performance
CHAPTER FIVE UNITED STATES TOURETTE SYNDROME DRUG BY COMPANIES 2012-2017
5.1 United States Tourette Syndrome Drug Sales Volume Market Share by Companies 2012-2017
5.2 United States Tourette Syndrome Drug Revenue Share by Companies 2012-2017
5.3 United States Top Companies Tourette Syndrome Drug Key Product Model and Market Performance
5.4 United States Top Companies Tourette Syndrome Drug Key Target Consumers and Market Performance
CHAPTER SIX GLOBAL TOURETTE SYNDROME DRUG BY CONSUMER 2012-2017
6.1 Global Tourette Syndrome Drug Sales Market Share by Consumer 2012-2017
6.2 Research Center
6.3 Hospital
6.4 Clinic
6.5 Others
6.6 Consuming Habit and Preference
CHAPTER SEVEN GLOBAL TOURETTE SYNDROME DRUG BY CONSUMER 2012-2017
7.1 Global Tourette Syndrome Drug Sales Market Share by Consumer 2012-2017
7.2 Research Center
7.3 Hospital
7.4 Clinic
7.5 Others
7.6 Consuming Habit and Preference
CHAPTER EIGHT TOP COMPANIES PROFILE
8.1 Abide Therapeutics Inc
8.1.1 Abide Therapeutics Inc Company Details and Competitors
8.1.2 Abide Therapeutics Inc Key Tourette Syndrome Drug Models and Performance
8.1.3 Abide Therapeutics Inc Tourette Syndrome Drug Business SWOT Analysis and Forecast
8.1.4 Abide Therapeutics Inc Tourette Syndrome Drug Sales Volume Revenue Price Cost and Gross Margin
8.2 Catalyst Pharmaceuticals Inc
8.2.1 Catalyst Pharmaceuticals Inc Company Details and Competitors
8.2.2 Catalyst Pharmaceuticals Inc Key Tourette Syndrome Drug Models and Performance
8.2.3 Catalyst Pharmaceuticals Inc Tourette Syndrome Drug Business SWOT Analysis and Forecast
8.2.4 Catalyst Pharmaceuticals Inc Tourette Syndrome Drug Sales Volume Revenue Price Cost and Gross Margin
8.3 Neurocrine Biosciences Inc
8.3.1 Neurocrine Biosciences Inc Company Details and Competitors
8.3.2 Neurocrine Biosciences Inc Key Tourette Syndrome Drug Models and Performance
8.3.3 Neurocrine Biosciences Inc Tourette Syndrome Drug Business SWOT Analysis and Forecast
8.3.4 Neurocrine Biosciences Inc Tourette Syndrome Drug Sales Volume Revenue Price Cost and Gross Margin
8.4 Psyadon Pharmaceuticals Inc
8.4.1 Psyadon Pharmaceuticals Inc Company Details and Competitors
8.4.2 Psyadon Pharmaceuticals Inc Key Tourette Syndrome Drug Models and Performance
8.4.3 Psyadon Pharmaceuticals Inc Tourette Syndrome Drug Business SWOT Analysis and Forecast
8.4.4 Psyadon Pharmaceuticals Inc Tourette Syndrome Drug Sales Volume Revenue Price Cost and Gross Margin
8.5 Reviva Pharmaceuticals Inc
8.5.1 Reviva Pharmaceuticals Inc Company Details and Competitors
8.5.2 Reviva Pharmaceuticals Inc Key Tourette Syndrome Drug Models and Performance
8.5.3 Reviva Pharmaceuticals Inc Tourette Syndrome Drug Business SWOT Analysis and Forecast
8.5.4 Reviva Pharmaceuticals Inc Tourette Syndrome Drug Sales Volume Revenue Price Cost and Gross Margin
8.6 Synchroneuron Inc
8.6.1 Synchroneuron Inc Company Details and Competitors
8.6.2 Synchroneuron Inc Key Tourette Syndrome Drug Models and Performance
8.6.3 Synchroneuron Inc Tourette Syndrome Drug Business SWOT Analysis and Forecast
8.6.4 Synchroneuron Inc Tourette Syndrome Drug Sales Volume Revenue Price Cost and Gross Margin
8.7 Teva Pharmaceutical Industries Ltd
8.7.1 Teva Pharmaceutical Industries Ltd Company Details and Competitors
8.7.2 Teva Pharmaceutical Industries Ltd Key Tourette Syndrome Drug Models and Performance
8.7.3 Teva Pharmaceutical Industries Ltd Tourette Syndrome Drug Business SWOT Analysis and Forecast
8.7.4 Teva Pharmaceutical Industries Ltd Tourette Syndrome Drug Sales Volume Revenue Price Cost and Gross Margin
8.8 Therapix Biosciences Ltd
8.8.1 Therapix Biosciences Ltd Company Details and Competitors
8.8.2 Therapix Biosciences Ltd Key Tourette Syndrome Drug Models and Performance
8.8.3 Therapix Biosciences Ltd Tourette Syndrome Drug Business SWOT Analysis and Forecast
8.8.4 Therapix Biosciences Ltd Tourette Syndrome Drug Sales Volume Revenue Price Cost and Gross Margin
CHAPTER NINE INDUSTRY CHAIN AND SUPPLY CHAIN
9.1 Tourette Syndrome Drug Industry Chain Structure
9.1.1 R&D
9.1.2 Raw Materials (Components)
9.1.3 Manufacturing Plants
9.1.4 Regional Trading (Import Export and Local Sales)
9.1.5 Online Sales Channel
9.1.6 Offline Channel
9.1.7 End Users
9.2 Tourette Syndrome Drug Manufacturing
9.2.1 Key Components
9.2.2 Assembly Manufacturing
9.3 Consumer Preference
9.4 Behavioral Habits
9.5 Marketing Environment
CHAPTER TEN GLOBAL TOURETTE SYNDROME DRUG MARKET SIZE (SALES AND REVENUE) FORECAST (2017-2022)
10.1 Global Tourette Syndrome Drug Sales (K Pcs), Revenue (Million USD) Forecast (2017-2022)
10.2 Global Tourette Syndrome Drug Sales (K Pcs) Forecast by Regions (2017-2022)
10.3 Global Tourette Syndrome Drug Sales (K Pcs) Forecast by Application (2017-2022)
10.4 Global Tourette Syndrome Drug Sales (K Pcs) Forecast by -5213 (2017-2022)
10.5 Global Tourette Syndrome Drug Sales (K Pcs) Forecast by -115 (2017-2022)
10.6 Global Tourette Syndrome Drug Sales (K Pcs) Forecast by etrabenazine ER (2017-2022)
10.7 Global Tourette Syndrome Drug Sales (K Pcs) Forecast by pipam Hydrochloride (2017-2022)
10.8 Global Tourette Syndrome Drug Sales (K Pcs) Forecast by ers (2017-2022)
CHAPTER ELEVEN UNITED STATES TOURETTE SYNDROME DRUG MARKET SIZE (SALES AND REVENUE) FORECAST (2017-2022)
11.1 United States Tourette Syndrome Drug Sales (K Pcs), Revenue (Million USD) Forecast (2017-2022)
11.2 United States Tourette Syndrome Drug Sales (K Pcs) Forecast by Regions (2017-2022)
11.3 United States Tourette Syndrome Drug Sales (K Pcs) Forecast by Application (2017-2022)
11.4 United States Tourette Syndrome Drug Sales (K Pcs) Forecast by -5213 (2017-2022)
11.5 United States Tourette Syndrome Drug Sales (K Pcs) Forecast by -115 (2017-2022)
11.6 United States Tourette Syndrome Drug Sales (K Pcs) Forecast by etrabenazine ER (2017-2022)
11.7 United States Tourette Syndrome Drug Sales (K Pcs) Forecast by pipam Hydrochloride (2017-2022)
11.8 United States Tourette Syndrome Drug Sales (K Pcs) Forecast by ers (2017-2022)
CHAPTER TWELVE DEVELOPMENT TREND AND RESEARCH CONCLUSION
12.1 Development Trend
12.2 Research Conclusion
CHAPTER THIRTEEN METHODOLOGY AND DATA SOURCE
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
LIST OF TABLES AND FIGURES
Table Global Tourette Syndrome Drug Sales Volume (K Pcs), Revenue (Million USD) and Price (USD/Pcs)(2012-2017)
Figure Global Tourette Syndrome Drug Revenue (Million USD) and Growth Rate (2012-2017)
Table Global Tourette Syndrome Drug Sales Volume (K Pcs), Revenue (Million USD) and Price (USD/Pcs)(2012-2017)
Figure Global Tourette Syndrome Drug Revenue (Million USD) and Growth Rate (2012-2017)
